Form 4: The Column Group Increases Stake in Surrozen, Inc. Through Private Placement

The Column Group III, LP and The Column Group III-A, LP acquired common stock and warrants in Surrozen, Inc. through a private placement on April 4, 2024, increasing their beneficial ownership.

Summary

• On April 4, 2024, The Column Group III, LP (TCG III LP) and The Column Group III-A, LP (TCG III-A LP) purchased common stock and warrants of Surrozen, Inc. through a private placement.
• TCG III LP acquired 90,897 shares of common stock and various series of warrants, while TCG III-A LP acquired 102,651 shares of common stock and corresponding warrants.
• The purchase price for the common stock and accompanying warrants was $15.50 per unit, with $14.25 attributable to each share and $1.25 to the warrants.
• The warrants include Series A, B, C, and D, each with different exercise conditions and expiration dates tied to clinical trial milestones for SZN-043, Surrozen's treatment for severe alcohol-associated hepatitis.
• The Column Group III GP, LP (TCG III GP) is the general partner of both TCG III LP and TCG III-A LP and may be deemed to have voting, investment, and dispositive power over the securities.
• The managing partners of TCG III GP are David Goeddel, Peter Svennilson, and Tim Kutzkey, with Tim Kutzkey being a member of Surrozen's board of directors.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the document reflects increased investment by a significant shareholder, indicating confidence in the company's future prospects. However, the warrant structure introduces some uncertainty related to clinical trial outcomes.

Positives

• Increased investment by The Column Group indicates confidence in Surrozen's prospects.
• The warrant exercise conditions are tied to specific clinical trial milestones, aligning investor interests with the company's progress.
• The private placement provides Surrozen with additional capital to fund its operations and clinical trials.

Risks

• The exercise of the warrants is contingent on achieving specific clinical trial milestones, which may not be met.
• Failure to meet these milestones could delay or prevent the exercise of the warrants, potentially impacting Surrozen's future funding.
• The value of the warrants is dependent on the success of the SZN-043 clinical trials.

Future Outlook

The exercise of the warrants is contingent upon the successful completion of clinical trial milestones related to SZN-043, Surrozen's treatment for severe alcohol-associated hepatitis, which will determine the future financial impact of these securities.

Industry Context

This investment reflects continued interest in the biotechnology sector, particularly in companies developing novel therapies for liver diseases. Private placements are a common funding mechanism for biotech companies, especially those in the clinical trial phase.

Comparison to Industry Standards

• Comparable companies in the biotech space, such as Viking Therapeutics and Madrigal Pharmaceuticals, have also utilized private placements to fund clinical trials.
• The warrant structure, with exercise conditions tied to clinical milestones, is a common practice to align investor interests with the company's progress, similar to deals seen with companies like Biohaven Pharmaceuticals.
• The size of the private placement is within the typical range for companies at Surrozen's stage of development, although specific comparisons would require a deeper analysis of their cash burn rate and funding needs.

Stakeholder Impact

• Shareholders may see a positive impact if the clinical trials are successful and the warrants are exercised.
• Employees may benefit from increased job security and potential for growth if the company is successful.
• Patients with severe alcohol-associated hepatitis may benefit from the development of a new treatment option.

Next Steps

• Surrozen will need to achieve the clinical trial milestones for SZN-043 to enable the exercise of the warrants.
• The Column Group will likely monitor Surrozen's progress and may adjust its investment strategy based on clinical trial results.
• Investors should monitor Surrozen's announcements regarding the progress of the SZN-043 clinical trials.

Key Dates